Kymera Therapeutics (KYMR) Research & Development (2019 - 2025)
Historic Research & Development for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $74.1 million.
- Kymera Therapeutics' Research & Development rose 2265.19% to $74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $304.6 million, marking a year-over-year increase of 3755.76%. This contributed to the annual value of $240.2 million for FY2024, which is 2706.09% up from last year.
- Per Kymera Therapeutics' latest filing, its Research & Development stood at $74.1 million for Q3 2025, which was up 2265.19% from $78.4 million recorded in Q2 2025.
- In the past 5 years, Kymera Therapeutics' Research & Development registered a high of $80.3 million during Q1 2025, and its lowest value of $26.0 million during Q1 2021.
- For the 5-year period, Kymera Therapeutics' Research & Development averaged around $50.7 million, with its median value being $45.8 million (2023).
- As far as peak fluctuations go, Kymera Therapeutics' Research & Development skyrocketed by 15486.65% in 2021, and later surged by 966.34% in 2023.
- Quarter analysis of 5 years shows Kymera Therapeutics' Research & Development stood at $37.5 million in 2021, then increased by 14.93% to $43.1 million in 2022, then increased by 22.81% to $53.0 million in 2023, then skyrocketed by 35.58% to $71.8 million in 2024, then increased by 3.17% to $74.1 million in 2025.
- Its last three reported values are $74.1 million in Q3 2025, $78.4 million for Q2 2025, and $80.3 million during Q1 2025.